Compare CLPS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLPS | BOLD |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 28.4M |
| IPO Year | 2018 | 2024 |
| Metric | CLPS | BOLD |
|---|---|---|
| Price | $0.92 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 22.4K | ★ 131.0K |
| Earning Date | 03-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 13.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $164,481,414.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.17 | N/A |
| 52 Week Low | $0.80 | $1.00 |
| 52 Week High | $1.88 | $2.54 |
| Indicator | CLPS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 46.13 |
| Support Level | $0.84 | $1.19 |
| Resistance Level | $0.90 | $1.31 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 85.71 | 12.50 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.